MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Cardiovascular
  • Orthopedics
  • Wall Street Beat
    • Funding Roundup
    • Mergers & Acquisitions
  • Podcasts
    • MPR: Breakthrough Products Series
  • Resources
    • About MassDevice
    • Newsletter Signup
    • Job Board
    • Leadership in Medtech
    • Manufacturer Search
    • Videos
    • Whitepapers
  • DeviceTalks
You are here: Home / Clinical Trials / Aortica touts FDA clearance to use Medtronic’s Valiant Navion in AAA IDE study

Aortica touts FDA clearance to use Medtronic’s Valiant Navion in AAA IDE study

December 17, 2018 By Fink Densford Leave a Comment

Medtronic, Aortica

Aortica said today that the FDA approved the use of Medtronic‘s (NYSE:MDT) Valiant Navion stent graft system alongside Aortica’s AortaFit in a physician sponsored IDE study.

The study, being run by principal investigator Dr. Benjamin Starnes at the University of Washington, will now use the Valiant Navion as a platform for fenestrated endovascular repair together with the AortaFit automated case planning software.

“I am excited to bring Medtronic’s Navion into this study. The device architecture incorporates many of the features we feel are important to simplifying fenestrated EVAR and addressing many of the issues that have limited physician acceptance of FEVAR in the past. In conjunction with Aortica’s automated graft planning technology, the Navion provides a combination of mechanical strength with ample available fabric area for placement of fenestrations. I am optimistic about the possibilities created by bringing these two technologies together,” Dr. Starnes said in a prepared statement.

The Navion device will be evaluated for its use in the treatment of complex juxtarenal abdominal aortic aneurysms, the Bellevue, Wash.-based company said. Aortica said that investigators in the study recently released early results for the AortaFit system designed to simplify AAA treatment.

“Accurately planning these cases using current technology and manual planning is challenging, time consuming and fraught with error. Consequently, surgeons tend to shy away from Fenestrated EVAR. By automating case planning to provide an accurate graft plan and coupling that with an appropriately designed endograft both the upfront planning and the procedure itself are dramatically simplified, and the endograft becomes ‘personalized’ to the individual patient’s anatomy. We believe this simplified, personalized approach will significantly increase the number of patients who are candidates for less invasive and personalized EVAR,” Aortica CEO Tom Douthitt said in a press release.

Last June, Aortica said that it raised $1 million in a round of mixed financing.

Filed Under: Clinical Trials, Food & Drug Administration (FDA), Vascular Tagged With: Aortica, Medtronic

In case you missed it

  • Employees say Intuitive Surgical, J&J, Stryker best places to work in 2020
  • Eitan Group signs service agreement with Integrated Medical Systems
  • Beta Bionics’ bionic pancreas wins breakthrough status from FDA
  • Sanofi backs away from diabetes partnership with Verily
  • FDA clears Cochlear piezoelectric hearing implant
  • Biolase lands 510(k) for dental hygiene laser
  • Mayo Clinic, W.L. Gore team up on stem cell therapy treatments
  • ViewRay issues urgent field safety notice for MRIdian System Treatment Planning and Delivery System
  • Barry out as InspireMD CEO
  • Report: EtO blood levels higher in Illinois neighbors of Medline sterilization plant
  • FDA clears augmented glenoids for Shoulder Innovations system
  • McKesson names new chief information and technology officer
  • Imperative Care raises $85m
  • CMR Surgical appoints new CEO
  • Peregrine Ventures raises $115m
  • Roche wins CE Mark for blood glucose reading smartphone app
  • Cantel Medical beats The Street in Q1 results

RSS From Medical Design & Outsourcing

Leave a Reply Cancel reply

You must be logged in to post a comment.

Need Medtech news in a minute?
We Deliver!

MassDevice Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Popular Posts

  • Report: SEC probes GE Healthcare, Philips, Siemens in Chinese bribery scheme
  • Edwards Lifesciences warns against below-market mini-tender offer Edwards Lifesciences
  • J&J’s Ethicon files ITC complaint against Intuitive Surgical Intuitive Surgical's EndoWrist instruments
  • Auris Health loses motion to move Intuitive Surgical patent suit from Del. to Cali. Johnson & Johnson's Auris, Intuitive Surgical
  • Enable Injections inks deal with Sanofi for drug delivery platform enfuse-enable-injections
Tweets by @MassDevice
MDO ad

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion

MASSDEVICE

Subscribe to MassDevice
Advertise with us
About
Contact us
Add us on FacebookMassDevice Network
Follow us on Twitter@MassDevice
Connect with us on LinkedInLinkedIn
Follow us on YouTube YouTube

Copyright © 2019 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS